An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program

This Italian study is reviewing real-world outcomes of patients with relapsed or treatment-resistant diffuse large B-cell lymphoma (DLBCL) who were treated with tafasitamab plus lenalidomide through a compassionate use program between April and December 2022. Researchers want to understand how well this combination works outside of clinical trials. **You may be eligible if...** - You are 18 or older - You have relapsed or refractory DLBCL - You received at least one dose of tafasitamab with lenalidomide through the Italian compassionate use program between April and December 2022 **You may NOT be eligible if...** - You received these drugs as part of a formal clinical trial (not through compassionate use) Talk to your doctor to see if this trial is right for you.